Literature DB >> 31216049

Interstitial lung disease in patients with common variable immunodeficiency disorders: several different pathologies?

S Patel1,2, C Anzilotti1,2, M Lucas1, N Moore3, H Chapel1,2,3.   

Abstract

Various reports of disease-related lung pathologies in common variable immunodeficiency disorder (CVID) patients have been published, with differing histological and high-resolution computed tomography (HRCT) findings. Data were extracted from the validated Oxford Primary Immune Deficiencies  Database (PID) database (1986-2016) on adult, sporadic CVID patients with suspected interstitial lung disease (ILD). Histology of lung biopsies was studied in relation to length of follow-up, clinical outcomes, HRCT findings and chest symptoms, to look for evidence for different pathological processes. Twenty-nine CVID patients with lung histology and/or radiological evidence of ILD were followed. After exclusions, lung biopsies from 16 patients were reanalysed for ILD. There were no well-formed granulomata, even though 10 patients had systemic, biopsy-proven granulomata in other organs. Lymphocytic infiltration without recognizable histological pattern was the most common finding, usually with another feature. On immunochemistry (n = 5), lymphocytic infiltration was due to T cells (CD4 or CD8). Only one patient showed B cell follicles with germinal centres. Interstitial inflammation was common; only four of 11 such biopsies also showed interstitial fibrosis. Outcomes were variable and not related to histology, suggesting possible different pathologies. The frequent nodules on HRCT were not correlated with histology, as there were no well-formed granulomata. Five patients were asymptomatic, so it is essential for all patients to undergo HRCT, and to biopsy if abnormal HRCT findings are seen. Internationally standardized pathology and immunochemical data are needed for longitudinal studies to determine the precise pathologies and prognoses in this severe complication of CVIDs, so that appropriate therapies may be found.
© 2019 Crown copyright. Clinical and Experimental Immunology © 2019 British Society for Immunology.

Entities:  

Keywords:  clinical outcomes; common variable immunodeficiency disorder; interstitial lung diseases; several pathologies; standardization of data

Year:  2019        PMID: 31216049      PMCID: PMC6797878          DOI: 10.1111/cei.13343

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.

Authors:  Paul J Maglione; Jessica R Overbey; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2015-09-12

2.  CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters.

Authors:  L J Maarschalk-Ellerbroek; P A de Jong; J M van Montfrans; J W J Lammers; A C Bloem; A I M Hoepelman; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2014-06-21       Impact factor: 8.317

3.  BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency.

Authors:  Paul J Maglione; Gavin Gyimesi; Montserrat Cols; Lin Radigan; Huaibin M Ko; Tamar Weinberger; Brian H Lee; Emilie K Grasset; Adeeb H Rahman; Andrea Cerutti; Charlotte Cunningham-Rundles
Journal:  JCI Insight       Date:  2019-03-07

4.  Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency--histologic and immunohistochemical analyses of 16 cases.

Authors:  Nagarjun Rao; A Craig Mackinnon; John M Routes
Journal:  Hum Pathol       Date:  2015-06-01       Impact factor: 3.466

Review 5.  Lung Disease in Primary Antibody Deficiencies.

Authors:  Edith Schussler; Mary B Beasley; Paul J Maglione
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

6.  Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency.

Authors:  Christopher A Bates; Misoo C Ellison; David A Lynch; Carlyne D Cool; Kevin K Brown; John M Routes
Journal:  J Allergy Clin Immunol       Date:  2004-08       Impact factor: 10.793

7.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes.

Authors:  Helen Chapel; Mary Lucas; Martin Lee; Janne Bjorkander; David Webster; Bodo Grimbacher; Claire Fieschi; Vojtech Thon; Mohammad R Abedi; Lennart Hammarstrom
Journal:  Blood       Date:  2008-03-04       Impact factor: 22.113

Review 8.  Detection of pulmonary complications in common variable immunodeficiency.

Authors:  Catharina M L Touw; Annick A van de Ven; Pim A de Jong; Suzanne Terheggen-Lagro; Erik Beek; Elisabeth A M Sanders; Joris M van Montfrans
Journal:  Pediatr Allergy Immunol       Date:  2009-11-13       Impact factor: 6.377

9.  Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency.

Authors:  Paul J Maglione; Huaibin M Ko; Mary B Beasley; James A Strauchen; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2013-10-13       Impact factor: 10.793

Review 10.  The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation.

Authors:  Ulrich Baumann; John M Routes; Pere Soler-Palacín; Stephen Jolles
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

View more
  10 in total

1.  Raised Serum Markers of T Cell Activation and Exhaustion in Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency.

Authors:  Mai Sasaki Aanensen Fraz; Annika Elisabet Michelsen; Natasha Moe; Trond Mogens Aaløkken; Magnhild Eide Macpherson; Ingvild Nordøy; Pål Aukrust; Eli Taraldsrud; Are Martin Holm; Thor Ueland; Silje Fjellgård Jørgensen; Børre Fevang
Journal:  J Clin Immunol       Date:  2022-07-05       Impact factor: 8.542

Review 2.  Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management.

Authors:  Paul J Maglione
Journal:  Immunol Allergy Clin North Am       Date:  2020-06-09       Impact factor: 3.479

3.  Adult Primary Antibody Deficiencies and the Lung.

Authors:  Ebru Damadoğlu
Journal:  Turk Thorac J       Date:  2021-05

Review 4.  Histology of Interstitial Lung Disease in Common Variable Immune Deficiency.

Authors:  Fatima Dhalla; Dylan J Mac Lochlainn; Helen Chapel; Smita Y Patel
Journal:  Front Immunol       Date:  2020-11-20       Impact factor: 7.561

5.  Interstitial Lung Disease in Common Variable Immunodeficiency.

Authors:  Joao Pedro Lopes; Hsi-En Ho; Charlotte Cunningham-Rundles
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

Review 6.  The pediatric common variable immunodeficiency - from genetics to therapy: a review.

Authors:  Aleksandra Szczawinska-Poplonyk; Eyal Schwartzmann; Ewelina Bukowska-Olech; Michal Biernat; Stanislaw Gattner; Tomasz Korobacz; Filip Nowicki; Monika Wiczuk-Wiczewska
Journal:  Eur J Pediatr       Date:  2021-12-23       Impact factor: 3.860

7.  Distinct CD8 T Cell Populations with Differential Exhaustion Profiles Associate with Secondary Complications in Common Variable Immunodeficiency.

Authors:  Bertram Bengsch; Klaus Warnatz; Adam Klocperk; David Friedmann; Alexandra Emilia Schlaak; Susanne Unger; Zuzana Parackova; Sigune Goldacker; Anna Sediva
Journal:  J Clin Immunol       Date:  2022-05-19       Impact factor: 8.542

8.  Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease.

Authors:  David Friedmann; Susanne Unger; Baerbel Keller; Mirzokhid Rakhmanov; Sigune Goldacker; Gernot Zissel; Björn C Frye; Jonas C Schupp; Antje Prasse; Klaus Warnatz
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

Review 9.  B Cell Dysregulation in Common Variable Immunodeficiency Interstitial Lung Disease.

Authors:  Erik M Matson; Miranda L Abyazi; Kayla A Bell; Kevin M Hayes; Paul J Maglione
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

10.  Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Authors:  Yulia Rodina; E Deripapa; O Shvets; A Mukhina; A Roppelt; D Yuhacheva; A Laberko; V Burlakov; D Abramov; G Tereshchenko; G Novichkova; Anna Shcherbina
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.